Nsclc Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Active, not recruiting
  • NSCLC
    • Ballarat, Australia
    • +253 more
    2022-01-13
    Jan 13, 2022
    T
    Recruiting
    • Non Small Cell Lung Cancer
    • +5 more
    • Orange, California
    • +12 more
    2022-01-12
    Jan 12, 2022
    R
    Recruiting
    • Cancer
    • +6 more
    • RP1
    • nivolumab
    • Gilbert, Arizona
    • +31 more
    2022-01-12
    Jan 12, 2022
    M
    Recruiting
    • NSCLC
    • +7 more
    • Hartford, Connecticut
    • +7 more
    2022-01-12
    Jan 12, 2022
    A
    Recruiting
    • Advanced Solid Tumors
    • +12 more
    • Continue PD-1/PD-L1 Inhibitors treatment
    • Discontinue PD-1/PD-L1-1 inhibitor
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    2021-12-22
    Dec 22, 2021
    S
    Recruiting
    • NSCLC
    • Poziotinib Once Daily Dosing
    • +2 more
    • Kashiwa, Chiba, Japan
    • +2 more
    2022-01-07
    Jan 7, 2022
    S
    Recruiting
    • NSCLC
    • Breast Cancer
    • Long Beach, California
    • +3 more
    2022-01-07
    Jan 7, 2022
    A
    Recruiting
    • Non-small Cell Lung Cancer
    • NSCLC
    • AMG 160
    • Camperdown, New South Wales, Australia
    • +1 more
    2021-12-21
    Dec 21, 2021
    A
    Enrolling by invitation
    • NSCLC
    • Online Survey
    • San Carlos, California
      Addario Lung Cancer Medical Institute
    2022-01-07
    Jan 7, 2022
    B
    Not yet recruiting
    • Solid Tumor, Adult
    • +8 more
    • BA3071
    • Nivolumab
    • (no location specified)
    2022-01-05
    Jan 5, 2022
    P
    Active, not recruiting
    • Advanced Solid Tumors
    • +7 more
    • TALZENNA capsule
    • Talazoparib soft gel capsule
    • Downey, California
    • +42 more
    2022-01-05
    Jan 5, 2022
    U
    Not yet recruiting
    • Nsclc
    • Blood sample
    • Montpellier, France
      University Hospital
    2021-12-30
    Dec 30, 2021
    S
    Recruiting
    • Non-small Cell Lung Cancer
    • NSCLC
    • Aarau, Switzerland
    • +12 more
    2021-12-24
    Dec 24, 2021
    V
    Recruiting
    • Triple-negative Breast Cancer
    • +14 more
    • Zilovertamab vedotin
    • Orlando, Florida
    • +2 more
    2021-12-05
    Dec 5, 2021
    N
    Active, not recruiting
    • NSCLC
    • +3 more
    • Boston, Massachusetts
    • +17 more
    2021-12-20
    Dec 20, 2021
    T
    Recruiting
    • NSCLC
    • EGF-R Positive Non-Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai General Hospital
    2021-12-20
    Dec 20, 2021
    P
    Not yet recruiting
    • NSCLC
    • +2 more
    • (no location specified)
    2021-12-06
    Dec 6, 2021
    N
    Active, not recruiting
    • Nonsmall Cell Lung Cancer
    • NSCLC
    • NovoTTF-200T
    • Immune checkpoint inhibitors or docetaxel
    • Birmingham, Alabama
    • +123 more
    2021-12-14
    Dec 14, 2021
    P
    Recruiting
    • Advanced Malignancies
    • +4 more
    • Koto, Tokyo, Japan
    • +2 more
    2021-12-14
    Dec 14, 2021